Search results for "Neuropsychopharmacology."

showing 5 items of 5 documents

Hippocampal overexpression of Nos1ap promotes endophenotypes related to mental disorders

2021

Abstract Background Nitric oxide synthase 1 adaptor protein (NOS1AP; previously named CAPON) is linked to the glutamatergic postsynaptic density through interaction with neuronal nitric oxide synthase (nNOS). NOS1AP and its interaction with nNOS have been associated with several mental disorders. Despite the high levels of NOS1AP expression in the hippocampus and the relevance of this brain region in glutamatergic signalling as well as mental disorders, a potential role of hippocampal NOS1AP in the pathophysiology of these disorders has not been investigated yet. Methods To uncover the function of NOS1AP in hippocampus, we made use of recombinant adeno-associated viruses to overexpress muri…

MaleMedicine (General)Research paperDendritic spineEndophenotypesNOS1APGene ExpressionHippocampusnNOS610 Medicine & healthNitric Oxide Synthase Type IHippocampal formationBiologyHippocampusSpatial memoryGeneral Biochemistry Genetics and Molecular BiologyMiceGlutamatergicR5-920NOS1APnitric oxideCAPONAnimalsNOS-I610 Medicine & healthAdaptor Proteins Signal TransducingMental DisordersRGeneral MedicineGlutamatergic postsynaptic densityNeuropsychopharmacologyDisease Models Animalpsychiatric disordersGene Expression Regulationnervous systemMedicineDisease SusceptibilityDisks Large Homolog 4 ProteinNeuroscienceBiomarkersProtein BindingSignal Transduction
researchProduct

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

Movement disorders/Parkinson’s diseaseDrug CarriersPolymersSurface PropertiesReviewsBrainAlzheimer's diseaseMultiple sclerosisDrug Delivery SystemsMovement disorders/Parkinson's diseaseSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoLiposomesNeuropsychopharmacology.AnimalsHumansNanoparticlesMultiple sclerosiParticle SizeNeuropsychopharmacologyAlzheimer’s diseaseMicellesCentral Nervous System Agents
researchProduct

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

PharmacologyDrugLiposomebusiness.industrymedia_common.quotation_subjectCentral nervous systemPharmacologyEndocytosisBrain diseaseNeuropsychopharmacologyPsychiatry and Mental healthmedicine.anatomical_structurePhysiology (medical)Drug deliveryMedicinePharmacology (medical)businessDrug carrierNeurosciencemedia_commonCNS Neuroscience & Therapeutics
researchProduct

French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs

2010

The prescription information (summary of product characteristics, SPC) is compiled by the pharmaceutical industry as required by the national regulatory authorities. They vary in their content about the properties of drugs and about the usefulness of therapeutic drug monitoring (TDM) in the blood of patients. Based on a previous study carried out in Germany, the degree of agreement of French SPC for 59 psychotropic drugs with the existing medico-scientific evidence in the area of TDM was examined using a recently developed instrument. A summary score of SPC content (SPCC) related to TDM (SPCC TDM ) has been calculated and compared with the level of recommendation of TDM of the AGNP-TDM expe…

PharmacologyDrugmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedia_common.quotation_subjectProduct characteristicsNeuropsychopharmacologyMoodTherapeutic drug monitoringmedicinePharmacology (medical)Summary of Product CharacteristicsMedical prescriptionPsychiatrybusinessmedia_commonPharmaceutical industryFundamental & Clinical Pharmacology
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct